Harnessing the HDAC–histone deacetylase enzymes, inhibitors and how these can be utilised in tissue engineering

Abstract

There are large knowledge gaps regarding how to control stem cells growth and differentiation. The limitations of currently available technologies, such as growth factors and/or gene therapies has led to the search of alternatives. We explore here how a cell’s epigenome influences determination of cell type, and potential applications in tissue engineering. A prevalent epigenetic modification is the acetylation of DNA core histone proteins. Acetylation levels heavily influence gene transcription. Histone deacetylase (HDAC) enzymes can remove these acetyl groups, leading to the formation of a condensed and more transcriptionally silenced chromatin. Histone deacetylase inhibitors (HDACis) can inhibit these enzymes, resulting in the increased acetylation of histones, thereby affecting gene expression. There is strong evidence to suggest that HDACis can be utilised in stem cell therapies and tissue engineering, potentially providing novel tools to control stem cell fate. This review introduces the structure/function of HDAC enzymes and their links to different tissue types (specifically bone, cardiac, neural tissues), including the history, current status and future perspectives of using HDACis for stem cell research and tissue engineering, with particular attention paid to how different HDAC isoforms may be integral to this field.

References

[1] Orlando G, . Regenerative medicine and organ transplantation: past, present, and future. Transplantation, 2011, 91: 1310-1317.

[2] Atala A, Bauer SB, Soker S, Yoo JJ, Retik AB. Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet, 2006, 367: 1241-1246.

[3] Tollervey JR, Lunyak VV. Epigenetics: judge, jury and executioner of stem cell fate. Epigenetics, 2012, 7: 823-840.

[4] Bird A. Perceptions of epigenetics. Nature, 2007, 447: 396-398.

[5] Dinarello CA, Fossati G, Mascagni P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol. Med., 2011, 17: 333-352.

[6] Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol. Oncol., 2007, 1: 19-25.

[7] Shakespear MR, Halili Ma, Irvine KM, Fairlie DP, Sweet MJ. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol., 2011, 32: 335-343.

[8] Hochedlinger K, Plath K. Epigenetic reprogramming and induced pluripotency. Development, 2009, 136: 509-523.

[9] Kretsovali A, Hadjimichael C, Charmpilas N. Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming. Stem Cells Int., 2012, 2012: 10.

[10] Elizalde C, . Histone deacetylase 3 modulates the expansion of human hematopoietic stem cells. Stem Cells Dev., 2012, 21: 2581-2591.

[11] Boer J, Licht R, Bongers M. Inhibition of histone acetylation as a tool in bone tissue engineering. Tissue Eng., 2006, 12: 2927-2937.

[12] Lee T, Lin M, Chang N. Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. Am. J. Physiol., 2007, 293: 968-977.

[13] Watson J, Crick F. A structure for deoxyribose nucleic acid. Nature, 1953, 171: 737-738.

[14] Hondele M, Ladurner AG. The chaperone-histone partnership: for the greater good of histone traffic and chromatin plasticity. Curr. Opin. Struct. Biol., 2011, 21: 698-708.

[15] Filippakopoulos P, Knapp S. The bromodomain interaction module. FEBS Lett., 2012, 586: 2692-2704.

[16] Strahl BD, Allis CD. The language of covalent histone modifications. Nature, 2000, 403: 41-45.

[17] Dhalluin C, . Structure and ligand of a histone acetyltransferase bromodomain. Nature, 1999, 399: 491-496.

[18] Ocker M. Deacetylase inhibitors-focus on non-histone targets and effects. World J. Biol. Chem., 2010, 1: 55-61.

[19] Bradner JE, . Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol., 2010, 6: 238-243.

[20] Uciechowska U, Sippl W, Jung M. NAA+-dependent histone deacetylases (Sirtuins) as novel therapeutic targets. Med. Res. Rev., 2009, 30: 861-889.

[21] Hahnen E, . Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opin. Investig. Drugs, 2008, 17: 169-184.

[22] Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: the next step?. Cancer Lett., 2009, 280: 211-221.

[23] Bertino EM, Otterson GA. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin. Investig. Drugs, 2011, 20: 1151-1158.

[24] Richardson P, . Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk. Lymphoma, 2008, 49: 502-507.

[25] Jones P. Development of second generation epigenetic agents. Med. Chem. Commun., 2012, 3: 135.

[26] Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets?. Cancer Lett., 2009, 277: 8-21.

[27] Bertrand P. Inside HDAC with HDAC inhibitors. Eur. J. Med. Chem., 2010, 45: 2095-2116.

[28] Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene, 2007, 26: 5541-5552.

[29] Nebbioso A, . Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med., 2005, 11: 77-84.

[30] Dokmanovic M, . Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol. Cancer Ther., 2007, 6: 2525-2534.

[31] Ohtani K, Dimmeler S. Epigenetic regulation of cardiovascular differentiation. Cardiovasc. Res., 2011, 90: 404-412.

[32] Hsieh J, Nakashima K, Kuwabara T, Mejia E, Gage FH. Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc. Natl Acad. Sci. USA, 2004, 101: 16659-16664.

[33] Catalioto R-M, Maggi CA, Giuliani S. Chemically distinct HDAC inhibitors prevent adipose conversion of subcutaneous human white preadipocytes at an early stage of the differentiation program. Exp. Cell Res., 2009, 315: 3267-3280.

[34] Duncan HF, Smith AJ, Fleming GJP, Cooper PR. HDACi: cellular effects, opportunities for restorative dentistry. J. Dent. Res., 2011, 90: 1377-1388.

[35] Duncan HF, Smith AJ, Fleming GJP, Cooper PR. Histone deacetylase inhibitors induced differentiation and accelerated mineralization of pulp-derived cells. J. Endod., 2012, 38: 339-345.

[36] Niki T, . A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology, 1999, 29: 858-867.

[37] Snykers S, De Kock J, Rogiers V, Vanhaecke T. In vitro differentiation of embryonic and adult stem cells into hepatocytes: state of the art. Stem Cells, 2009, 27: 577-605.

[38] Knutson SK, . Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks. EMBO J., 2008, 27: 1017-1028.

[39] Kurinna S, Barton MC. Cascades of transcription regulation during liver regeneration. Int. J. Biochem. Cell Biol., 2011, 43: 189-197.

[40] Glenisson W, Castronovo V, Waltregny D. Histone deacetylase 4 is required for TGFβ1 -induced myofibroblastic differentiation. Biochim. Biophys. Acta, 2007, 1773: 1572-1582.

[41] Avrahami D, Kaestner KH. Epigenetic regulation of pancreas development and function. Semin. Cell Dev. Biol., 2012, 23: 693-700.

[42] Kim M-S, . Protein kinase D1 stimulates MEF2 activity in skeletal muscle and enhances muscle performance. Mol. Cell. Biol., 2008, 28: 3600-3609.

[43] Hong S, Derfoul A, Pereira-Mouries L, Hall DJ. A novel domain in histone deacetylase 1 and 2 mediates repression of cartilage-specific genes in human chondrocytes. FASEB J., 2009, 23: 3539-3552.

[44] Li H, . Expression of acetylated histone 3 in the spinal cord and the effect of morphine on inflammatory pain. Neural Regen. Res., 2012, 7: 517-522.

[45] Naguib M, Bie B, Ting AH. Fundamental concepts of epigenetics for consideration in anesthesiology. Curr. Opin. Anaesthesiol., 2012, 25: 434-443.

[46] Denk F, McMahon SB. Chronic pain: emerging evidence for the involvement of epigenetics. Neuron, 2012, 73: 435-444.

[47] Chiechio S, . Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain. Mol. Pharmacol., 2009, 75: 1014-1020.

[48] Zhang Z, Cai Y-Q, Zou F, Bie B, Pan ZZ. Epigenetic suppression of GAD65 expression mediates persistent pain. Nat. Med., 2011, 17: 1448-1455.

[49] Steinmann J, Halldórsson S, Agerberth B, Gudmundsson GH. Phenylbutyrate induces antimicrobial peptide expression. Antimicrob. Agents Chemother., 2009, 53: 5127-5133.

[50] Schildberg FA, Hagmann CA, Böhnert V, Tolba RH. Improved transplantation outcome by epigenetic changes. Transpl. Immunol., 2010, 23: 104-110.

[51] Kinugasa F, . Effect of a new immunosuppressant histon deacetylase (HDAC) inhibitor FR276457 in a rat cardiac transplant model. Biol. Pharm. Bull., 2008, 31: 1723-1726.

[52] Reddy P, . Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl Acad. Sci. USA, 2004, 101: 3921-3926.

[53] Choi S, Reddy P. HDAC inhibition and graft versus host disease. Mol. Med., 2011, 17: 404-416.

[54] Bhavsar P, Ahmad T, Adcock IM. The role of histone deacetylases in asthma and allergic diseases. J. Allergy Clin. Immunol., 2008, 121: 580-584.

[55] Kim T-I, Han J-E, Jung H-M, Oh J-H, Woo KM. Analysis of histone deacetylase inhibitor-induced responses in human periodontal ligament fibroblasts. Biotechnol. Lett., 2013, 35: 129-133.

[56] El-Gendy R, Yang X. Osteogenic differentiation of human dental pulp stromal cells on 45S5 Bioglass® based scaffolds in vitro and in vivo. Tissue Eng. Part A, 2012, 19: 707-715.

[57] Saha S, . Osteochondral tissue engineering in vivo: a comparative study using layered silk fibroin scaffolds from mulberry and nonmulberry silkworms. PLoS ONE, 2013, 8

[58] Yang X, . Induction of human osteoprogenitor chemotaxis, proliferation, differentiation, and bone formation by osteoblast stimulating factor-1/pleiotrophin: osteoconductive biomimetic scaffolds for tissue engineering. J. Bone Miner. Res., 2003, 18: 47-57.

[59] Vater C, Kasten P, Stiehler M. Culture media for the differentiation of mesenchymal stromal cells. Acta Biomater., 2011, 7: 463-477.

[60] Iwami K, Moriyama T. Effects of short chain fatty acid, sodium butyrate, on osteoblastic cells and osteoclastic cells. Int. J. Biochem., 1993, 25: 1631-1635.

[61] Nissen-Meyer LSH, . Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. Epilepsia, 2007, 48: 1850-1860.

[62] Senn SM, . Adverse effects of valproate on bone: defining a model to investigate the pathophysiology. Epilepsia, 2010, 51: 984-993.

[63] McGee-Lawrence ME, . Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. Bone, 2011, 48: 1117-1126.

[64] Pratap J, . The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol. Cancer Ther., 2010, 9: 3210-3220.

[65] Xu S, . Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. Acta Pharmacol. Sin., 2013, 34: 699-709.

[66] Schroeder TM, Westendorf JJ. Histone deacetylase inhibitors promote osteoblast maturation. J. Bone Miner. Res., 2005, 20: 2254-2263.

[67] Schroeder TM, Kahler RA, Li X, Westendorf JJ. Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J. Biol. Chem., 2004, 279: 41998-42007.

[68] Razidlo DF, . Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS ONE, 2010, 5

[69] McGee-Lawrence ME, . Histone deacetylase 3 is required for maintenance of bone mass during aging. Bone, 2013, 52: 296-307.

[70] Hesse E, . Zfp521 controls bone mass by HDAC3-dependent attenuation of Runx2 activity. J. Cell Biol., 2010, 191: 1271-1283.

[71] Lamour V, Detry C, Sanchez C. Runx2-and histone deacetylase 3-mediated repression is relieved in differentiating human osteoblast cells to allow high bone sialoprotein expression. J. Biol. Chem., 2007, 282: 36240-36249.

[72] Choo M, Yeo H, Zayzafoon M. NFATc1 mediates HDAC-dependent transcriptional repression of osteocalcin expression during osteoblast differentiation. Bone, 2009, 45: 579-589.

[73] Shen J, . Histone acetylation in vivo at the osteocalcin locus is functionally linked to vitamin D-dependent, bone tissue-specific transcription. J. Biol. Chem., 2002, 277: 20284-20292.

[74] Lee HW, . Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Mol. Endocrinol., 2006, 20: 2432-2443.

[75] Fu Y, . Histone deacetylase 8 suppresses osteogenic differentiation of bone marrow stromal cells by inhibiting histone H3K9 acetylation and RUNX2 activity. Int. J. Biochem. Cell Biol., 2014, 54: 68-77.

[76] Kang JS, Alliston T, Delston R, Derynck R. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J., 2005, 24: 2543-2555.

[77] Jeon E-J, . Bone morphogenetic protein-2 stimulates Runx2 acetylation. J. Biol. Chem., 2006, 281: 16502-16511.

[78] Vega RB, . Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell, 2004, 119: 555-566.

[79] Huang S, . Upregulation of miR-22 promotes osteogenic differentiation and inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells by repressing HDAC6 protein expression. Stem Cells Dev., 2012, 21: 2531-2540.

[80] Cantley MD, . Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro. J. Cell. Physiol., 2011, 226: 3233-3241.

[81] Nakamura T, . Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J. Immunol., 2005, 175: 5809-5816.

[82] Pham L, . HDAC3 and HDAC7 have opposite effects on osteoclast differentiation. J. Biol. Chem., 2011, 286: 12056-12065.

[83] Kim JH, . RANKL induces NFATc1 acetylation and stability via histone acetyltransferases during osteoclast differentiation. Biochem. J., 2011, 436: 253-262.

[84] Desiderio V, Tirino V, Papaccio G, Paino F. Bone defects: molecular and cellular therapeutic targets. Int. J. Biochem. Cell Biol., 2014, 51: 75-78.

[85] Montecino M, . Chromatin hyperacetylation abrogates vitamin D-mediated transcriptional upregulation of the tissue-specific osteocalcin gene in vivo. Biochemistry, 1999, 38: 1338-1345.

[86] Schroeder TM, Nair AK, Staggs R, Lamblin A-F, Westendorf JJ. Gene profile analysis of osteoblast genes differentially regulated by histone deacetylase inhibitors. BMC Genom., 2007, 8

[87] Kim H-N, . Histone deacetylase inhibitor MS-275 stimulates bone formation in part by enhancing Dhx36-mediated TNAP transcription. J. bone Miner. Res., 2011, 26: 2161-2173.

[88] Kim H-N, . MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice. Eur. J. Pharmacol., 2012, 691: 69-76.

[89] Rahman MM, . Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood, 2003, 101: 3451-3459.

[90] Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J. Biol. Chem., 2006, 281: 5612-5622.

[91] Yi T, Baek J. Trichostatin A-mediated upregulation of p21 osteoclast apoptosis. Exp. Mol. Med., 2007, 39: 213-221.

[92] Cantley MD, Bartold PM, Fairlie DP, Rainsford KD, Haynes DR. Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases. J. Pharm. Pharmacol., 2012, 64: 763-774.

[93] Fan X, . Regulation of RANKL promoter activity is associated with histone remodeling in murine bone stromal cells. J. Cell. Biochem., 2004, 93: 807-818.

[94] Lee S-U, . In vitro and in vivo osteogenic activity of largazole. ACS Med. Chem. Lett., 2011, 2: 248-251.

[95] Paino F, . Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement. Stem Cells, 2014, 32: 279-289.

[96] Jin H, Park J, Choi H, Choung P. HDAC inhibitor trichostatin a promotes proliferation and odontoblast differentiation of human dental pulp stem cells. Tissue Eng. Part A, 2013, 19: 613-624.

[97] Huynh NCN, Everts V, Ampornaramveth RS. Histone deacetylases and their roles in mineralized tissue regeneration. Bone Rep., 2017, 7: 33-40.

[98] Jung H-M, . Modulation of the resorption and osteoconductivity of alpha-calcium sulfate by histone deacetylase inhibitors. Biomaterials, 2010, 31: 29-37.

[99] Maroni P, . Chemical and genetic blockade of HDACs enhances osteogenic differentiation of human adipose tissue-derived stem cells by oppositely affecting osteogenic and adipogenic transcription factors. Biochem. Biophys. Res. Commun., 2012, 428: 271-277.

[100] Xu Y, . Inhibition of histone deacetylase activity in reduced oxygen environment enhances the osteogenesis of mouse adipose-derived stromal cells. Tissue Eng. Part A, 2009, 15: 3697-3707.

[101] Cho HH, . Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors. J. Cell. Biochem., 2005, 96: 533-542.

[102] Nunes SS, Song H, Chiang CK, Radisic M. Stem cell-based cardiac tissue engineering. J. Cardiovasc. Transl. Res., 2011, 4: 592-602.

[103] Zhou B, Margariti A, Zeng L, Xu Q. Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis. Cardiovasc. Res., 2011, 90: 413-420.

[104] McKinsey Ta. Therapeutic potential for HDAC inhibitors in the heart. Annu. Rev. Pharmacol. Toxicol., 2012, 52: 303-319.

[105] Granger A, . Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J., 2008, 22: 3549-3560.

[106] McKinsey TA, Olson EN. Cardiac histone acetylation -therapeutic opportunities abound. Trends Genet., 2004, 20: 206-213.

[107] Hewitson Ruth, Dargan James, Collis David, Green Aneta, Moorjani Narain, Ohri Sunil, Townsend Paul A.. Heart failure: The pivotal role of histone deacetylases. The International Journal of Biochemistry & Cell Biology, 2013, 45(2): 448-453.

[108] McKinsey TA. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart. J. Mol. Cell. Cardiol., 2011, 51: 491-496.

[109] Lehmann Lorenz H., Worst Barbara C., Stanmore David A., Backs Johannes. Histone deacetylase signaling in cardioprotection. Cellular and Molecular Life Sciences, 2013, 71(9): 1673-1690.

[110] Cardinale JP, . HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension, 2010, 56: 437-444.

[111] Yang G, . Trichostatin a promotes cardiomyocyte differentiation of rat mesenchymal stem cells after 5-azacytidine induction or during coculture with neonatal cardiomyocytes via a mechanism independent of histone deacetylase inhibition. Cell Transplant., 2012, 21: 985-996.

[112] Papait R, . Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. Proc. Natl Acad. Sci. USA, 2013, 110: 20164-20169.

[113] Vunjak-Novakovic G, . Challenges in cardiac tissue engineering. Tissue Eng. Part B. Rev., 2010, 16: 169-187.

[114] Teng M, Zhao X, Huang Y. Regenerating cardiac cells: insights from the bench and the clinic. Cell Tissue Res., 2012, 350: 189-197.

[115] Montgomery RL, . Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev., 2007, 21: 1790-1802.

[116] Zhang C, McKinsey T, Chang S, Antos C. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell, 2002, 110: 479-488.

[117] Trivedi CM, . HDAC2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat. Med., 2007, 13: 324-331.

[118] Chang S, . Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell, 2006, 126: 321-334.

[119] Lu D-F, . Knockdown of the HDAC1 promotes the directed differentiation of bone mesenchymal stem cells into cardiomyocytes. PLoS ONE, 2014, 9

[120] Trivedi CM, Lu MM, Wang Q, Epstein JA. Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy. J. Biol. Chem., 2008, 283: 26484-26489.

[121] Montgomery RL, . Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J. Clin. Invest., 2008, 118: 3588-3597.

[122] Chen HP, . HDAC inhibition promotes cardiogenesis and the survival of embryonic stem cells through proteasome-dependent pathway. J. Cell. Biochem., 2011, 112: 3246-3255.

[123] Chang S, McKinsey T. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell. Biol., 2004, 24: 8467-8476.

[124] Chow MZY, . Epigenetic regulation of the electrophysiological phenotype of human embryonic stem cell-derived ventricular cardiomyocytes: insights for driven maturation and hypertrophic growth. Stem Cells Dev., 2013, 22: 2678-2690.

[125] Reichert N, Choukrallah M-A, Matthias P. Multiple roles of class I HDACs in proliferation, differentiation, and development. Cell. Mol. Life Sci., 2012, 69: 2173-2187.

[126] Feng C, . Suberoylanilide hydroxamic acid promotes cardiomyocyte differentiation of rat mesenchymal stem cells. Exp. Cell Res., 2009, 315: 3044-3051.

[127] Choi YS, . Differentiation of human adipose-derived stem cells into beating cardiomyocytes. J. Cell. Mol. Med., 2010, 14: 878-889.

[128] Oyama T, . Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo. J. Cell Biol., 2007, 176: 329-341.

[129] Kaichi S, . Cell line-dependent differentiation of induced pluripotent stem cells into cardiomyocytes in mice. Cardiovasc. Res., 2010, 88: 314-323.

[130] Kawamura T, . Acetylation of GATA-4 is involved in the differentiation of embryonic stem cells into cardiac myocytes. J. Biol. Chem., 2005, 280: 19682-19688.

[131] Kaichi S, . Cyclin-dependent kinase 9 forms a complex with GATA4 and is involved in the differentiation of mouse ES cells into cardiomyocytes. J. Cell. Physiol., 2011, 226: 248-254.

[132] Otsuji TG, Kurose Y, Suemori H, Tada M, Nakatsuji N. Dynamic link between histone H3 acetylation and an increase in the functional characteristics of human ESC/iPSC-derived cardiomyocytes. PLoS ONE, 2012, 7

[133] Karamboulas C, . HDAC activity regulates entry of mesoderm cells into the cardiac muscle lineage. J. Cell Sci., 2006, 119: 4305-4314.

[134] Zhang L, . Inhibition of histone deacetylase-induced myocardial repair is mediated by c-kit in infarcted hearts. J. Biol. Chem., 2012, 287: 39338-39348.

[135] Lee S, Wolfe S. Peripheral nerve injury and repair. J. Am. Acad. Orthop. Surg., 2000, 8: 243-252.

[136] Chen S, Wu H, Klebe D, Hong Y, Zhang J. Valproic acid: a new candidate of therapeutic application for the acute central nervous system injuries. Neurochem. Res., 2014, 39: 1621-1633.

[137] Hao Y, . Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J. Neurosci., 2004, 24: 6590-6599.

[138] Brochier C, . Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons. J. Neurosci., 2013, 33: 8621-8632.

[139] Phiel CJ, . Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem., 2001, 276: 36734-36741.

[140] Göttlicher M, . Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J., 2001, 20: 6969-6978.

[141] Bell JHA, Haycock JW. Next generation nerve guides: materials, fabrication, growth factors, and cell delivery. Tissue Eng. Part B Rev., 2012, 18: 116-128.

[142] Hu X-L, Wang Y, Shen Q. Epigenetic control on cell fate choice in neural stem cells. Protein Cell, 2012, 3: 278-290.

[143] Forraz N, Wright KE, Jurga M, Mcguckin CP. Experimental therapies for repair of the central nervous system : stem cells and tissue engineering. J. Tissue Eng. Regen. Med., 2013, 7: 523-536.

[144] Ballas N, Grunseich C, Lu DD, Speh JC, Mandel G. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell, 2005, 121: 645-657.

[145] Sun G, Yu RT, Evans RM, Shi Y. Orphan nuclear receptor TLX recruits histone deacetylases to repress transcription and regulate neural stem cell proliferation. Proc. Natl Acad. Sci. USA, 2007, 104: 15282-15287.

[146] MacDonald JL, Roskams AJ. Histone deacetylases 1 and 2 are expressed at distinct stages of neuro-glial development. Dev. Dyn., 2008, 237: 2256-2267.

[147] Yamaguchi M, . Histone deacetylase 1 regulates retinal neurogenesis in zebrafish by suppressing Wnt and Notch signaling pathways. Development, 2005, 132: 3027-3043.

[148] Akhtar MW, . Histone deacetylases 1 and 2 form a developmental switch that controls excitatory synapse maturation and function. J. Neurosci., 2009, 29: 8288-8297.

[149] Romm E, Nielsen JA, Kim JG, Hudson LD. Myt1 family recruits histone deacetylase to regulate neural transcription. J. Neurochem., 2005, 93: 1444-1453.

[150] Shen S, Li J, Casaccia-Bonnefil P. Histone modifications affect timing of oligodendrocyte progenitor differentiation in the developing rat brain. J. Cell Biol., 2005, 169: 577-589.

[151] Bai S, . DNA methyltransferase 3b regulates nerve growth factor-induced differentiation of PC12 cells by recruiting histone deacetylase 2. Mol. Cell. Biol., 2005, 25: 751-766.

[152] Ballas N, . Regulation of neuronal traits by a novel transcriptional complex. Neuron, 2001, 31: 353-365.

[153] Roopra A, . Transcriptional repression by neuron-restrictive silencer factor is mediated via the Sin3-histone deacetylase complex. Mol. Cell. Biol., 2000, 20: 2147-2157.

[154] Humphrey GW, . Complementary roles for histone deacetylases 1, 2, and 3 in differentiation of pluripotent stem cells. Differentiation, 2008, 76: 348-356.

[155] Ye F, . HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat. Neurosci., 2009, 12: 829-838.

[156] Chen Y, . HDAC-mediated deacetylation of NF-κB is critical for Schwann cell myelination. Nat. Neurosci., 2011, 14: 437-441.

[157] Conway GD, O’Bara Ma, Vedia BH, Pol SU, Sim FJ. Histone deacetylase activity is required for human oligodendrocyte progenitor differentiation. Glia, 2012, 60: 1944-1953.

[158] Montgomery RL, Hsieh J, Barbosa AC, Richardson JA, Olson EN. Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development. Proc. Natl Acad. Sci. USA, 2009, 106: 7876-7881.

[159] Zupkovitz G, . Negative and positive regulation of gene expression by mouse histone deacetylase 1. Mol. Cell. Biol., 2006, 26: 7913-7928.

[160] Jawerka M, . The specific role of histone deacetylase 2 in adult neurogenesis. Neuron Glia Biol., 2010, 6: 93-107.

[161] Panteleeva I, . HDAC-3 participates in the repression of e2f-dependent gene transcription in primary differentiated neurons. Ann. N. Y. Acad. Sci., 2004, 1030: 656-660.

[162] McQuown SC, . HDAC3 is a critical negative regulator of long-term memory formation. J. Neurosci., 2011, 31: 764-774.

[163] Morrison BE, Majdzadeh N, D’Mello SR. Histone deacetylases: focus on the nervous system. Cell. Mol. Life Sci., 2007, 64: 2258-2269.

[164] Majdzadeh N, . HDAC4 inhibits cell cycle progression and protects neurons from cell death. Dev. Neurobiol., 2008, 68: 1076-1092.

[165] Schneider JW, . Small-molecule activation of neuronal cell fate. Nat. Chem. Biol., 2008, 4: 408-410.

[166] d’Ydewalle C, Bogaert E, Van Den Bosch L. HDAC6 at the intersection of neuroprotection and neurodegeneration. Traffic, 2012, 13: 771-779.

[167] Méjat A, . Histone deacetylase 9 couples neuronal activity to muscle chromatin acetylation and gene expression. Nat. Neurosci., 2005, 8: 313-321.

[168] Liu H, Hu Q, Kaufman A, D’Ercolem J, Ye P. Developmental expression of histone deacetylase 11 in the murine brain. J. Neurosci. Res., 2008, 86: 537-543.

[169] Lois C, Alvarez-Buylla A. Proliferating subventricular zone cells in the adult mammalian forebrain can differentiate into neurons and glia. Proc. Natl Acad. Sci. USA, 1993, 90: 2074-2077.

[170] Reynolds B, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science, 1992, 255: 1707-1710.

[171] Alvarez-Buylla A, Temple S. Stem cells in the developing and adult nervous system. J. Neurobiol., 1998, 36: 105-110.

[172] McKay R. Stem cells in the central nervous system. Science, 1997, 276: 66-71.

[173] Gurvich N. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res., 2004, 64: 1079-1086.

[174] Gibbons HM, . Valproic acid induces microglial dysfunction, not apoptosis, in human glial cultures. Neurobiol. Dis., 2011, 41: 96-103.

[175] Jung G-A, . Valproic acid induces differentiation and inhibition of proliferation in neural progenitor cells via the beta-catenin-Ras-ERK-p21Cip/WAF1 pathway. BMC Cell Biol., 2008, 9

[176] Yu IT, . Valproic acid promotes neuronal differentiation by induction of proneural factors in association with H4 acetylation. Neuropharmacology, 2009, 56: 473-480.

[177] Juliandi B, . Induction of superficial cortical layer neurons from mouse embryonic stem cells by valproic acid. Neurosci. Res., 2012, 72: 23-31.

[178] Zhou Q, Dalgard CL, Wynder C, Doughty ML. Valproic acid inhibits neurosphere formation by adult subventricular cells by a lithium-sensitive mechanism. Neurosci. Lett., 2011, 500: 202-206.

[179] Lv L, Han X, Sun Y, Wang X, Dong Q. Valproic acid improves locomotion in vivo after SCI and axonal growth of neurons in vitro. Exp. Neurol., 2012, 233: 783-790.

[180] Balasubramaniyan V, . Effects of histone deacetylation inhibition on neuronal differentiation of embryonic mouse neural stem cells. Neuroscience, 2006, 143: 939-951.

[181] Siebzehnrubl FA, . Histone deacetylase inhibitors increase neuronal differentiation in adult forebrain precursor cells. Exp. Brain Res., 2007, 176: 672-678.

[182] Rössler R, Boddeke E, Copray S. Differentiation of non-mesencephalic neural stem cells towards dopaminergic neurons. Neuroscience, 2010, 170: 417-428.

[183] Lyssiotis CA, . Inhibition of histone deacetylase activity induces developmental plasticity in oligodendrocyte precursor cells. Proc. Natl Acad. Sci. USA, 2007, 104: 14982-14987.

[184] Lv L, . Valproic acid improves outcome after rodent spinal cord injury: potential roles of histone deacetylase inhibition. Brain Res., 2011, 1396: 60-68.

[185] Abematsu M, . Neurons derived from transplanted neural stem cells restore disrupted neuronal circuitry in a mouse model of spinal cord injury. J. Clin. Invest., 2010, 120: 3255-3266.

[186] Jin W, Peng J, Jiang S. The epigenetic regulation of embryonic myogenesis and adult muscle regeneration by histone methylation modification. Biochem. Biophys. Rep., 2016, 6: 209-219.

[187] Bassel-Duby R, Olson EN. Signaling pathways in skeletal muscle remodeling. Annu. Rev. Biochem., 2006, 75: 19-37.

[188] McKinsey TA, Zhang CL, Olson EN. Control of muscle development by dueling HATs and HDACs. Curr. Opin. Genet. Dev., 2001, 11: 497-504.

[189] Mckinsey TA, Zhang C, Lu J, Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature, 2000, 408: 106-111.

[190] Moresi V, Marroncelli N, Coletti D, Adamo S. Regulation of skeletal muscle development and homeostasis by gene imprinting, histone acetylation and micro RNA. Biochim. Biophys. Acta, 2015, 1849: 309-316.

[191] Fischer A, Sananbenesi F, Mungenast A, Tsai L-H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci., 2010, 31: 605-617.

[192] Suraweera A, O’Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front. Oncol., 2018, 8: 1-15.

[193] De Ruijter AJM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J., 2003, 370: 737-749.

[194] Yang W-M, Yao Y-L, Sun J-M, Davie JR, Seto E. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J. Biol. Chem., 1997, 272: 28001-28007.

[195] Lagger G, . Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J., 2002, 21: 2672-2681.

[196] Zupkovitz G, . The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol. Cell. Biol., 2010, 30: 1171-1181.

[197] Wilting RH, . Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J., 2010, 29: 2586-2597.

[198] Yamaguchi T, . Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev., 2010, 24: 455-469.

[199] Miller KM, . Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat. Struct. Mol. Biol., 2010, 17: 1144-1151.

[200] Kim D, . Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron, 2008, 60: 803-817.

[201] Jacob C, . HDAC1 and HDAC2 control the transcriptional program of myelination and the survival of Schwann cells. Nat. Neurosci., 2011, 14: 429-436.

[202] Moresi V, . Histone deacetylases 1 and 2 regulate autophagy flux and skeletal muscle homeostasis in mice. Proc. Natl Acad. Sci. USA, 2012, 109: 1649-1654.

[203] Grausenburger R, . Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J. Immunol., 2010, 185: 3489-3497.

[204] LeBoeuf Matthew, Terrell Anne, Trivedi Sohum, Sinha Satrajit, Epstein Jonathan A., Olson Eric N., Morrisey Edward E., Millar Sarah E.. Hdac1 and Hdac2 Act Redundantly to Control p63 and p53 Functions in Epidermal Progenitor Cells. Developmental Cell, 2010, 19(6): 807-818.

[205] Haberland M, Carrer M, Mokalled MH, Montgomery RL, Olson EN. Redundant control of adipogenesis by histone deacetylases 1 and 2. J. Biol. Chem., 2010, 285: 14663-14670.

[206] Guan J-S, . HDAC2 negatively regulates memory formation and synaptic plasticity. Nature, 2009, 459: 55-60.

[207] Bhaskara S, . Deletion of Histone Deacetylase 3 reveals critical roles in S-phase progression and DNA damage control. Mol. Cell, 2009, 30: 61-72.

[208] Jiang Y, Hsieh J. HDAC3 controls gap 2/mitosis progression in adult neural stem/progenitor cells by regulating CDK1 levels. Proc. Natl Acad. Sci. USA, 2014, 111: 13541-13546.

[209] Feng D, . A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science, 2011, 331: 1315-1320.

[210] Haberland M, Mokalled MH, Montgomery L, Olson EN. Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev., 2009, 23: 1625-1630.

[211] Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet., 2003, 19: 286-293.

[212] Zhao X, . The modular nature of histone deacetylase HDAC4 confers phosphorylation-dependent intracellular trafficking. J. Biol. Chem., 2001, 276: 35042-35048.

[213] Chen B, Cepko CL. HDAC4 regulates neuronal survival in normal and diseased retinas. Science, 2009, 323: 256-259.

[214] Bolger T, Yao T-P. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J. Neurosci., 2005, 25: 9544-9553.

[215] Bolger T, Zhao X, Cohen TJ, Tsai C-C, Yao T-P. The neurodegenerative disease protein ataxin-1 antagonizes the neuronal survival function of myocyte enhancer factor-2. J. Biol. Chem., 2007, 282: 29186-29192.

[216] Chawla S, Vanhoutte P, Arnold FJL, Huang CL-H, Bading H. Neuronal activity-dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5. J. Neurochem., 2003, 85: 151-159.

[217] Mckinsey TA, Zhang C, Lu J, Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Lett. Nat., 2000, 408: 106-111.

[218] Agis-Balboa RC, Pavelka Z, Kerimoglu C, Fischer A. Loss of HDAC5 impairs memory function: implications for Alzheimer’s disease. J. Alzheimers Dis., 2013, 33: 35-44.

[219] Dequiedt F, . HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity, 2003, 18: 687-698.

[220] Ji H, . A comprehensive methylome map of lineage commitment from hematopoietic progenitors. Nature, 2010, 467: 338-342.

[221] Shakespear MR, . Histone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophages. J. Biol. Chem., 2013, 288: 25362-25374.

[222] Zhou X, Marks PA, Rifkind RA, Richon VM. Cloning and characterization of a histone deacetylase, HDAC9. Proc. Natl Acad. Sci. USA, 2001, 98: 10572-10577.

[223] Balasubramanian A, . Fam65b is important for formation of the HDAC6-dysferlin protein complex during myogenic cell differentiation. FASEB J., 2014, 28: 2955-2969.

[224] Zhang D, . Activation of histone deacetylase-6 induces contractile dysfunction through derailment of α-tubulin proteostasis in experimental and human atrial fibrillation. Circulation, 2014, 129: 346-358.

[225] Gradilone SA, . HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis. Am. J. Pathol., 2014, 184: 600-608.

[226] Liu W, . HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells. PLoS ONE, 2012, 7

[227] Zhang Y, . Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell. Biol., 2008, 28: 1688-1701.

[228] Boyault C, . HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev., 2007, 21: 2172-2181.

[229] Kwon S, Zhang Y, Matthias P. The deacetylase HDAC6 is an essential component of stress granules and plays a critical role in the cellular response to stress Inauguraldissertation. Genes Dev., 2007, 21: 3381-3394.

[230] Lee J-Y, . HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J., 2010, 29: 969-980.

[231] Sadoul K, . HDAC6 controls the kinetics of platelet activation. Platelets Thrombopoiesis, 2015, 120: 4215-4219.

[232] Kao H-Y, Lee C-H, Komarov A, Han CC, Evans RM. Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. J. Biol. Chem., 2002, 277: 187-193.

[233] Lai I-L, . Histone deacetylase 10 relieves repression on the melanogenic program by maintaining the deacetylation status of repressors. J. Biol. Chem., 2010, 285: 7187-7196.

[234] Oehme I, . Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc. Natl Acad. Sci. USA, 2013, 110: E2592-E2601.

[235] Gao L, Cueto Ma, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem., 2002, 277: 25748-25755.

[236] Villagra A, . The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat. Immunol., 2008, 10: 92-100.

[237] Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIS): Multitargeted anticancer agents. Biol. Targets Ther., 2013, 7: 47-60.

[238] Khan N, . Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J., 2008, 409: 581-589.

[239] Hu Erding, . Identification of novel isoform-selective inhibitors within Class I histone deacetylases. J. Pharmacol. Exp. Ther., 2003, 307: 720-728.

Funding

RCUK | Engineering and Physical Sciences Research Council (EPSRC)(EP/L014823/1, EP/L014823/1)

British Council(UKIERI-TRP-2012/13-030 (IND/CONT/E/12-13/695))